NASDAQ:CNTGCentogene Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Centogene N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $12.31 -0.47 (-3.68 %) (As of 08/12/2020 04:00 PM ET) Add Compare Share Today's Range$12.11Now: $12.31▼$12.7550-Day Range$11.55MA: $16.36▼$24.5052-Week Range$7.80Now: $12.31▼$28.71Volume109,100 shsAverage Volume79,110 shsMarket Capitalization$244.49 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartCompetitorsEarningsInstitutional OwnershipHeadlinesShort InterestSocial Media Centogene B.V. operates as a commercial-stage rare disease company worldwide. It focuses on transforming clinical and genetic data into medical solutions for patients, physicians, and pharmaceutical companies. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It operates through two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment offers various services, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Diagnostics segment provides genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. Centogene B.V. was founded in 2006 and is headquartered in Rostock, Germany.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingCentogene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.00, Centogene has a potential upside of 62.5% from its current price of $12.31.Amount of Analyst CoverageCentogene has received no research coverage in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesCentogene has received 25 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCentogene has received 25 “underperform” votes. (Add your “underperform” vote.)Community SentimentCentogene has received 50.00% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Centogene and other stocks. Vote “Outperform” if you believe CNTG will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CNTG will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCentogene does not currently pay a dividend.Dividend GrowthCentogene does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Centogene insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 8.35% of the stock of Centogene is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Centogene are expected to grow in the coming year, from ($1.74) to ($1.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Centogene is -8.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Centogene is -8.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCentogene has a P/B Ratio of 3.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.33 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CNTG Previous Symbol CUSIPN/A CIKN/A Webwww.centogene.com Phone49-3818-011-3500Debt Debt-to-Equity Ratio0.38 Current Ratio1.98 Quick Ratio1.79Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$54.64 million Price / Sales4.47 Cash FlowN/A Price / Cash FlowN/A Book Value$3.32 per share Price / Book3.71Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees400 Outstanding Shares19,861,000Market Cap$244.49 million Next Earnings Date9/21/2020 (Estimated) OptionableNot Optionable $12.31 -0.47 (-3.68 %) (As of 08/12/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CNTG News and Ratings via Email Sign-up to receive the latest news and ratings for CNTG and its competitors with MarketBeat's FREE daily newsletter. Centogene (NASDAQ:CNTG) Frequently Asked Questions How has Centogene's stock price been impacted by COVID-19? Centogene's stock was trading at $18.80 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CNTG stock has decreased by 34.5% and is now trading at $12.31. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Centogene? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Centogene in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Centogene. When is Centogene's next earnings date? Centogene is scheduled to release its next quarterly earnings announcement on Monday, September 21st 2020. View our earnings forecast for Centogene. How were Centogene's earnings last quarter? Centogene N.V. (NASDAQ:CNTG) announced its earnings results on Monday, June, 15th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by $0.10. The firm earned $13.35 million during the quarter, compared to the consensus estimate of $13.78 million. View Centogene's earnings history. What price target have analysts set for CNTG? 4 equities research analysts have issued 1-year target prices for Centogene's stock. Their forecasts range from $17.00 to $23.00. On average, they anticipate Centogene's stock price to reach $20.00 in the next year. This suggests a possible upside of 62.5% from the stock's current price. View analysts' price targets for Centogene. Has Centogene been receiving favorable news coverage? News coverage about CNTG stock has been trending somewhat negative recently, according to InfoTrie Sentiment. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Centogene earned a media sentiment score of -1.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about Centogene. Who are some of Centogene's key competitors? Some companies that are related to Centogene include RadNet (RDNT), Fulgent Genetics (FLGT), Castle Biosciences (CSTL), Personalis (PSNL), ALX Oncology (RNLX), Progenity (PROG), DermTech (DMTK), Biocept (BIOC), Enzo Biochem (ENZ), Anpac Bio-Medical Science (ANPC), Miragen Therapeutics (MGEN), Celcuity (CELC), OpGen (OPGN), Psychemedics (PMD) and PotNetwork (POTN). View all competitors. What other stocks do shareholders of Centogene own? Based on aggregate information from My MarketBeat watchlists, some companies that other Centogene investors own include Fulcrum Therapeutics (FULC), Alimera Sciences (ALIM), Entasis Therapeutics (ETTX), Gold Standard Ventures (GSV), Gold Standard Ventures (GSV), VBI Vaccines (VBIV), VIVUS (VVUS), Acasti Pharma (ACST), Aldeyra Therapeutics (ALDX) and AngloGold Ashanti (AU). Who are Centogene's key executives? Centogene's management team includes the following people: Prof. Arndt Rolfs, CEO, Chief Medical Officer & Member of Management Board (Age 60)Mr. Richard Stoffelen, CFO & Member of Management Board (Age 52)Dr. Dirk H. Ehlers, COO, Pres of Clinical Diagnostics & Member of Management Board (Age 58)Dr. Volkmar Weckesser Ph.D., Chief Information Officer & Member of Management Board (Age 52)Prof. Peter Bauer M.D., Chief Scientific Officer (Age 50) When did Centogene IPO? (CNTG) raised $60 million in an initial public offering (IPO) on Thursday, November 7th 2019. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. SVB Leerink and Evercore ISI served as the underwriters for the IPO and Baird and BTIG were co-managers. What is Centogene's stock symbol? Centogene trades on the NASDAQ under the ticker symbol "CNTG." Who are Centogene's major shareholders? Centogene's stock is owned by many different institutional and retail investors. Top institutional shareholders include Platinum Investment Management Ltd. (0.30%), Bank of New York Mellon Corp (0.05%) and New York State Common Retirement Fund (0.03%). Which major investors are buying Centogene stock? CNTG stock was acquired by a variety of institutional investors in the last quarter, including Platinum Investment Management Ltd., Bank of New York Mellon Corp, and New York State Common Retirement Fund. How do I buy shares of Centogene? Shares of CNTG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Centogene's stock price today? One share of CNTG stock can currently be purchased for approximately $12.31. How big of a company is Centogene? Centogene has a market capitalization of $244.49 million and generates $54.64 million in revenue each year. The company earns $-23,360,000.00 in net income (profit) each year or ($1.46) on an earnings per share basis. Centogene employs 400 workers across the globe. What is Centogene's official website? The official website for Centogene is www.centogene.com. How can I contact Centogene? Centogene's mailing address is AM STRANDE 7, ROSTOCK 2M, 18055. The company can be reached via phone at 49-3818-011-3500 or via email at [email protected] This page was last updated on 8/12/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
